Cell: Heavyweight! Chinese scientists have successfully mapped a comprehensive proteomic map of human lung adenocarcinoma!

July 15, 2020 // In a recent study published in the international journal Cell, scientists from the Shanghai Institute of Pharmaceutical Research of the Chinese Academy of Sciences conducted a comprehensive proteomic analysis of 103 patients with Lung Adenocarcinoma in China, the leading cause of death in all cancers in the worldphoto source: CC0 Public Domain article, researchers reveal the molecular characteristics associated with lung adenocarcinoma, and the association between these molecular characteristics and patientclinical prognosis, potential prognostic biomarkers, and drug targets;in order to fully understand the molecular profile blueprint of lung adenocarcinoma and provide opportunities for the development of more accurate lung adenocarcinoma diagnostic techniques and therapies, researchers conducted a complete proteomic and phosphated proteomic analysis of tumor tissue sandintissues in 103 patients, identifying 11,119 proteins and 22,564 phosphorylation sites, combining these protein data, clinical information, and genomics datathe researchers found that epithelial interstitial conversion (EMT) and inflammatory and cancerous signaling pathways may cause poor prognosis in patients with stage 1 lung adenocarcinoma, and then the researchers established a link between genomic change and protein properties in patients with EGFR or TP53 mutations, the dominant gene driving the incidence of lung adenocarcinoma in Chinathe researchers later found that two histological markers (TTF-1 and tthanine protease A) and special proteins in the spline were at higher expression levels in patients with EGFR mutations, and in patients with TP53 mutations, a variety of cancer-causing pathways, including DNA replication and mismatch repair, also changed significantlyresearchers divided all patients with lung adenocarcinoma into three proteomic subtypes, namely S-1, S-II and S-III, each with different molecular and clinical characteristics, comprehensive bioinformatics analysis showed that S-I patients are directly related to cell environment and good prognosis, compared with S-II patients with cell proliferation, protein group stability and adverse prognosis Directcorrelation; Phosphinized proteomic analysis results show editing of activated signaling pathways and kinases in patients with different proteomic subtypes, and when researchers combined proteomic data and clinical data, they identified 27 potential plasma biomarkers and a variety of lung adenocarcinoma drug targets, of which potential biomarkers called HSP 90 beta may need to be confirmed in a later independent studythis study provides scientists with new ideas for deepinterpretation of lung adenocarcinoma in addition to the current genome research, and in clinical practice, proteomics databases may be used as a valuable and powerful resource to accelerate the transformation of basic research into more accurate diagnostic techniques and therapeutic therapiesOriginal origins from: Jun-Yu Xu, Chunchao Zhang, Xiang Wang, et alIntegrative Proteomicization to Human Lung Adenocarcinoma, Cell (2020) doi: 10.1016/j.cell.2020.05.043